Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.

Gold JS, Ferrone CR, Guevara-Patiño JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN.

J Immunol. 2003 May 15;170(10):5188-94.

2.

Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense.

Messaoudi I, Guevara Patiño JA, Dyall R, LeMaoult J, Nikolich-Zugich J.

Science. 2002 Nov 29;298(5599):1797-800.

3.

Age-related dysregulation in CD8 T cell homeostasis: kinetics of a diversity loss.

LeMaoult J, Messaoudi I, Manavalan JS, Potvin H, Nikolich-Zugich D, Dyall R, Szabo P, Weksler ME, Nikolich-Zugich J.

J Immunol. 2000 Sep 1;165(5):2367-73.

4.

Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.

Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ.

Surgery. 2000 Aug;128(2):273-80.

PMID:
10923004
5.

MHC polymorphism can enrich the T cell repertoire of the species by shifts in intrathymic selection.

Dyall R, Messaoudi I, Janetzki S, Nikolic-Zugić J.

J Immunol. 2000 Feb 15;164(4):1695-8.

6.

Coupling and uncoupling of tumor immunity and autoimmunity.

Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN.

J Exp Med. 1999 Dec 6;190(11):1717-22.

8.

Cellular basis of B cell clonal populations in old mice.

LeMaoult J, Manavalan JS, Dyall R, Szabo P, Nikolic-Zugic J, Weksler ME.

J Immunol. 1999 Jun 1;162(11):6384-91.

9.

Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor.

Dyall R, Vasovic LV, Clynes RA, Nikolić-Zugić J.

Eur J Immunol. 1999 Jan;29(1):30-7.

10.

Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization.

Ross HM, Weber LW, Wang S, Piskun G, Dyall R, Song P, Takechi Y, Nikolić-Zugić J, Houghton AN, Lewis JJ.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2191-6.

11.

Heteroclitic immunization induces tumor immunity.

Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolić-Zugić J.

J Exp Med. 1998 Nov 2;188(9):1553-61.

12.

Maturation of B cell precursors is impaired in thymic-deprived nude and old mice.

Szabo P, Zhao K, Kirman I, Le Maoult J, Dyall R, Cruikshank W, Weksler ME.

J Immunol. 1998 Sep 1;161(5):2248-53.

13.

The critical role of a solvent-exposed residue of an MHC class I-restricted peptide in MHC-peptide binding.

Huard R, Dyall R, Nikolić-Zugić J.

Int Immunol. 1997 Nov;9(11):1701-7.

PMID:
9418131
14.

Clonal expansions of B lymphocytes in old mice.

LeMaoult J, Delassus S, Dyall R, Nikolić-Zugić J, Kourilsky P, Weksler ME.

J Immunol. 1997 Oct 15;159(8):3866-74.

PMID:
9378974
15.

Synergy between an antibody and CD8+ cells in eliminating an established tumor.

Vasović LV, Dyall R, Clynes RA, Ravetch JV, Nikolić-Zugic J.

Eur J Immunol. 1997 Feb;27(2):374-82.

PMID:
9045907
17.

CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens.

Dyall R, Vasović LV, Molano A, Nikolić-Zugić J.

Int Immunol. 1995 Aug;7(8):1205-12.

PMID:
7495727
19.

Bone marrow declines as a site of B-cell precursor differentiation with age: relationship to thymus involution.

Ben-Yehuda A, Szabo P, Dyall R, Weksler ME.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11988-92.

20.

A positively selecting thymic epithelial cell line lacks costimulatory activity.

Vukmanović S, Stella G, King PD, Dyall R, Hogquist KA, Harty JT, Nikolić-Zugić J, Bevan MJ.

J Immunol. 1994 Apr 15;152(8):3814-23.

PMID:
7511660
21.

Supplemental Content

Support Center